These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7543969)

  • 1. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
    Kapur S; Remington G; Zipursky RB; Wilson AA; Houle S
    Life Sci; 1995; 57(10):PL103-7. PubMed ID: 7543969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
    Farde L; Nyberg S; Oxenstierna G; Nakashima Y; Halldin C; Ericsson B
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):19S-23S. PubMed ID: 7537284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
    Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects.
    Farde L; Mack RJ; Nyberg S; Halldin C
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S3-7. PubMed ID: 9179638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapyramidal side effects and tolerability of risperidone: a review.
    Owens DG
    J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
    Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone.
    Nyberg S; Dahl ML; Halldin C
    Psychopharmacology (Berl); 1995 Jun; 119(3):345-8. PubMed ID: 7545821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
    Kapur S; Zipursky R; Remington G; Jones C; McKay G; Houle S
    Am J Psychiatry; 1997 Nov; 154(11):1525-9. PubMed ID: 9356559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.